Sheng Zhao

Sheng Zhao

Auto-generated profile, based on publicly available information

Sheng Zhao

Innovative Genomics Institute, Berkeley, United States & University of California-Berkeley, Berkeley, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
KCKai Chen
Kai Chen
HHHesong Han
Hesong Han
SZSheng Zhao
Sheng Zhao
BXBryant Xu
Bryant Xu
BYBoyan Yin
Boyan Yin
JDJennifer A. Doudna
Jennifer A. Doudna
Lipid nanoparticle (LNP) delivery of clustered regularly interspaced short palindromic repeat (CRISPR) ribonucleoproteins (RNPs) could enable high-efficiency, low-toxicity and scalable in vivo genome editing if efficacious RNP–LNP complexes can be reliably produced. Here we engineer a thermostable Cas9 from Geobacillus stearothermophilus (GeoCas9) to generate iGeoCas9 variants capable of >100× more genome editing of cells and organs compared with the native GeoCas9 enzyme. Furthermore, iGeoCas9 RNP–LNP complexes edit a variety of cell types and induce homology-directed repair in cells receiving codelivered single-stranded DNA templates. Using tissue-selective LNP formulations, we observe genome-editing levels of 16‒37% in the liver and lungs of reporter mice that receive single intravenous injections of iGeoCas9 RNP–LNPs. In addition, iGeoCas9 RNPs complexed to biodegradable LNPs edit the disease-causing SFTPC gene in lung tissue with 19% average efficiency, representing a major improvement over genome-editing levels observed previously using viral or nonviral delivery strategies. These results show that thermostable Cas9 RNP–LNP complexes can expand the therapeutic potential of genome editing.

23 August 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
SZSheng Zhao
Sheng Zhao
KGKewa Gao
Kewa Gao
HHHesong Han
Hesong Han
MSMichael Stenzel
Michael Stenzel
BYBoyan Yin
Boyan Yin
Niren MurthyNiren Murthy
Niren Murthy

3 November 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
GNGabriel Neiman
Gabriel Neiman
MCMauro W. Costa
Mauro W. Costa
HHHesong Han
Hesong Han
SZSheng Zhao
Sheng Zhao
TNTammy K. Ng
Tammy K. Ng
KHKevin E. Healy
Kevin E. Healy

16 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CBChristopher M Baehr
Christopher M Baehr
ARAlzbeta Ressnerova
Alzbeta Ressnerova
MKMin Kang
Min Kang
SZSheng Zhao
Sheng Zhao
BLBeatrice Le
Beatrice Le
RWRoss C Wilson
Ross C Wilson
Delivery remains the main obstacle to the development of in vivo genome editing therapies. CRISPR ribonucleoproteins confer high editing activity with transient exposure but lack intrinsic cell entry and targeting. Here we introduce PERCEPT, a delivery platform featuring reversible, covalent modification of CRISPR enzymes. PERCEPT enables modular installation of shielding polymers, amphiphilic delivery peptides and targeting ligands, allowing traceless cytosolic release of the native editor. A formulation incorporating an amphiphilic delivery peptide and the neuron-targeting ligand TET1 edited approximately 56% of striatal volume and 78% of neurons within edited regions after local striatal administration. In the R6/2 Huntington's disease model, PERCEPT mediated targeted editing of the mutant human HTT transgene, reducing mutant huntingtin aggregate burden and shifting local transcriptional programs away from inflammatory and injury-associated states. Tissue-adapted formulations edited 53% of Muller glia following intravitreal delivery, increased skeletal muscle reporter fluorescence tenfold versus unconjugated control following intramuscular injection, and enabled lung airway epithelial cell that persisted for three months following intranasal delivery. Rapid screening revealed that local anatomical and cellular barriers require distinct surface display for optimal editing. These results establish reversible chemical modification as a general strategy for adapting CRISPR enzyme delivery across multiple target tissues in vivo.

18 June 2026 in Nature Biotechnology
Verified
Journal Article
Open access
KCKai Chen
Kai Chen
HHHesong Han
Hesong Han
SZSheng Zhao
Sheng Zhao
BXBryant Xu
Bryant Xu
BYBoyan Yin
Boyan Yin
JDJennifer A. Doudna
Jennifer A. Doudna